News Medical on MSN1d
Parkinson's disease drug disrupts the gut microbiome by inducing iron deficiencyIn a groundbreaking new study, conducted within the framework of the FWF-funded Cluster of Excellence "Microbiomes drive ...
Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s diseaseARISE will ...
2don MSNOpinion
The Medical College of Wisconsin created a neurology department 50 years ago. Today with Froedtert it is world leader in ...
A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...
CHINA: A 70-year-old man from Henan Province in central China has developed Parkinson’s disease after enduring decades of ...
There's no cure for Parkinson's ... physical and psychosocial effects of rock climbing on individuals with Parkinson's disease Mark de Mulder, a musician and former director of the National ...
Parkinson's disease cases will rise to 3.15 million by 2033. The increase will be seen in seven countries including the US, ...
Pharmaceutical Technology on MSN9d
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefitAC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...
GlobalData on MSN12d
DMTs are major clinical research focus for Parkinson’s disease, analysis showsGlobalData analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's ...
News Medical on MSN4d
New protein target offers promise for alleviating cognitive decline in Parkinson's diseaseA recently published study by researchers at the University of Arizona Health Sciences found that a tiny protein called PNA5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback